Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer

Toshiaki Saeki, Atsushi Okita, Kenjiro Aogi, Tomokazu Kakishita, Riki Okita, Naruto Taira, Yumi Ohama, Shigemitsu Takashima, Kiyohiro Nishikawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Multidrug resistance protein could be a target for improving the efficacy of paclitaxel (PXL). Toremifene (TOR) may moderate P-gp-related drug resistance in vitro. Some P-gp moderators may change the pharmacokinetic parameters of PXL in vivo. A pharmacokinetic (PK) study in metastatic breast cancer patients (MBC) was conducted to determine the safety and efficacy of PXL and TOR. Method and patients: Fifteen patients received 80 mg/m2 PXL (i.v.) weekly and 120 mg/body TOR (p.o.) daily. For the pharmacokinetic study, PXL was administered on days 1, 8, 15, 32, and 39; TOR was given from day 18 to the end of study. On days 1, 8, 15, 18, 32, and 39, blood samples were collected from the patients who received either PXL alone or PXL + TOR, and these were analyzed by high-performance liquid chromatography. Results: Among the 15 patients enrolled in the study, one showed a partial response, and eight had a stable disease. TOR caused no specific adverse events that were greater than grade 3, and its toxicity profile in combination with PXL was similar to that of PXL monotherapy. The PK profile of PXL was similar with or without TOR. The PK parameters of PXL indicated no inter- or intra-patient variability in previously treated patients with MBC. No increased PXL toxicity was observed. Conclusion: The PK profile of combined PXL and TOR was similar to that of PXL monotherapy. The addition of TOR to PXL in previously treated patients with MBC appears safe.

Original languageEnglish
Pages (from-to)113-120
Number of pages8
JournalBreast Cancer
Volume16
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Toremifene
Paclitaxel
Pharmacokinetics
Breast Neoplasms
Therapeutics
P-Glycoproteins

Keywords

  • Antiestrogens
  • Breast cancer
  • Chemoendocrine therapy
  • Drug resistance
  • Paclitaxel
  • Toremifene

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)
  • Radiology Nuclear Medicine and imaging

Cite this

Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer. / Saeki, Toshiaki; Okita, Atsushi; Aogi, Kenjiro; Kakishita, Tomokazu; Okita, Riki; Taira, Naruto; Ohama, Yumi; Takashima, Shigemitsu; Nishikawa, Kiyohiro.

In: Breast Cancer, Vol. 16, No. 2, 2009, p. 113-120.

Research output: Contribution to journalArticle

Saeki, T, Okita, A, Aogi, K, Kakishita, T, Okita, R, Taira, N, Ohama, Y, Takashima, S & Nishikawa, K 2009, 'Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer', Breast Cancer, vol. 16, no. 2, pp. 113-120. https://doi.org/10.1007/s12282-008-0075-7
Saeki, Toshiaki ; Okita, Atsushi ; Aogi, Kenjiro ; Kakishita, Tomokazu ; Okita, Riki ; Taira, Naruto ; Ohama, Yumi ; Takashima, Shigemitsu ; Nishikawa, Kiyohiro. / Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer. In: Breast Cancer. 2009 ; Vol. 16, No. 2. pp. 113-120.
@article{2df496cdb25f4936b305b117efe8fe8d,
title = "Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer",
abstract = "Background: Multidrug resistance protein could be a target for improving the efficacy of paclitaxel (PXL). Toremifene (TOR) may moderate P-gp-related drug resistance in vitro. Some P-gp moderators may change the pharmacokinetic parameters of PXL in vivo. A pharmacokinetic (PK) study in metastatic breast cancer patients (MBC) was conducted to determine the safety and efficacy of PXL and TOR. Method and patients: Fifteen patients received 80 mg/m2 PXL (i.v.) weekly and 120 mg/body TOR (p.o.) daily. For the pharmacokinetic study, PXL was administered on days 1, 8, 15, 32, and 39; TOR was given from day 18 to the end of study. On days 1, 8, 15, 18, 32, and 39, blood samples were collected from the patients who received either PXL alone or PXL + TOR, and these were analyzed by high-performance liquid chromatography. Results: Among the 15 patients enrolled in the study, one showed a partial response, and eight had a stable disease. TOR caused no specific adverse events that were greater than grade 3, and its toxicity profile in combination with PXL was similar to that of PXL monotherapy. The PK profile of PXL was similar with or without TOR. The PK parameters of PXL indicated no inter- or intra-patient variability in previously treated patients with MBC. No increased PXL toxicity was observed. Conclusion: The PK profile of combined PXL and TOR was similar to that of PXL monotherapy. The addition of TOR to PXL in previously treated patients with MBC appears safe.",
keywords = "Antiestrogens, Breast cancer, Chemoendocrine therapy, Drug resistance, Paclitaxel, Toremifene",
author = "Toshiaki Saeki and Atsushi Okita and Kenjiro Aogi and Tomokazu Kakishita and Riki Okita and Naruto Taira and Yumi Ohama and Shigemitsu Takashima and Kiyohiro Nishikawa",
year = "2009",
doi = "10.1007/s12282-008-0075-7",
language = "English",
volume = "16",
pages = "113--120",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer

AU - Saeki, Toshiaki

AU - Okita, Atsushi

AU - Aogi, Kenjiro

AU - Kakishita, Tomokazu

AU - Okita, Riki

AU - Taira, Naruto

AU - Ohama, Yumi

AU - Takashima, Shigemitsu

AU - Nishikawa, Kiyohiro

PY - 2009

Y1 - 2009

N2 - Background: Multidrug resistance protein could be a target for improving the efficacy of paclitaxel (PXL). Toremifene (TOR) may moderate P-gp-related drug resistance in vitro. Some P-gp moderators may change the pharmacokinetic parameters of PXL in vivo. A pharmacokinetic (PK) study in metastatic breast cancer patients (MBC) was conducted to determine the safety and efficacy of PXL and TOR. Method and patients: Fifteen patients received 80 mg/m2 PXL (i.v.) weekly and 120 mg/body TOR (p.o.) daily. For the pharmacokinetic study, PXL was administered on days 1, 8, 15, 32, and 39; TOR was given from day 18 to the end of study. On days 1, 8, 15, 18, 32, and 39, blood samples were collected from the patients who received either PXL alone or PXL + TOR, and these were analyzed by high-performance liquid chromatography. Results: Among the 15 patients enrolled in the study, one showed a partial response, and eight had a stable disease. TOR caused no specific adverse events that were greater than grade 3, and its toxicity profile in combination with PXL was similar to that of PXL monotherapy. The PK profile of PXL was similar with or without TOR. The PK parameters of PXL indicated no inter- or intra-patient variability in previously treated patients with MBC. No increased PXL toxicity was observed. Conclusion: The PK profile of combined PXL and TOR was similar to that of PXL monotherapy. The addition of TOR to PXL in previously treated patients with MBC appears safe.

AB - Background: Multidrug resistance protein could be a target for improving the efficacy of paclitaxel (PXL). Toremifene (TOR) may moderate P-gp-related drug resistance in vitro. Some P-gp moderators may change the pharmacokinetic parameters of PXL in vivo. A pharmacokinetic (PK) study in metastatic breast cancer patients (MBC) was conducted to determine the safety and efficacy of PXL and TOR. Method and patients: Fifteen patients received 80 mg/m2 PXL (i.v.) weekly and 120 mg/body TOR (p.o.) daily. For the pharmacokinetic study, PXL was administered on days 1, 8, 15, 32, and 39; TOR was given from day 18 to the end of study. On days 1, 8, 15, 18, 32, and 39, blood samples were collected from the patients who received either PXL alone or PXL + TOR, and these were analyzed by high-performance liquid chromatography. Results: Among the 15 patients enrolled in the study, one showed a partial response, and eight had a stable disease. TOR caused no specific adverse events that were greater than grade 3, and its toxicity profile in combination with PXL was similar to that of PXL monotherapy. The PK profile of PXL was similar with or without TOR. The PK parameters of PXL indicated no inter- or intra-patient variability in previously treated patients with MBC. No increased PXL toxicity was observed. Conclusion: The PK profile of combined PXL and TOR was similar to that of PXL monotherapy. The addition of TOR to PXL in previously treated patients with MBC appears safe.

KW - Antiestrogens

KW - Breast cancer

KW - Chemoendocrine therapy

KW - Drug resistance

KW - Paclitaxel

KW - Toremifene

UR - http://www.scopus.com/inward/record.url?scp=65249090187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249090187&partnerID=8YFLogxK

U2 - 10.1007/s12282-008-0075-7

DO - 10.1007/s12282-008-0075-7

M3 - Article

C2 - 18936884

AN - SCOPUS:65249090187

VL - 16

SP - 113

EP - 120

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 2

ER -